Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.

Chan HW, Ashan B, Jayasekera P, Collier A, Ghosh S.

Diabetes Metab Syndr. 2012 Oct-Dec;6(4):224-8. doi: 10.1016/j.dsx.2012.08.003. Epub 2012 Oct 16. Review.

PMID:
23199545
2.

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

Whalen K, Miller S, Onge ES.

Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16. Review.

PMID:
25891804
3.

Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.

Davidson JA, Kuritzky L.

Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819. Review.

PMID:
25414933
4.

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.

Jabbour SA, Goldstein BJ.

Int J Clin Pract. 2008 Aug;62(8):1279-84. doi: 10.1111/j.1742-1241.2008.01829.x. Review.

PMID:
18705823
5.

[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].

Pérez López G, González Albarrán O, Cano Megías M.

Nefrologia. 2010;30(6):618-25. doi: 10.3265/Nefrologia.pre2010.Sep.10494. Review. Spanish.

6.

SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.

Kilov G, Leow S, Thomas M.

Aust Fam Physician. 2013 Oct;42(10):706-10. Review.

7.

[New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].

Simonyi G.

Orv Hetil. 2012 May 6;153(18):695-701. doi: 10.1556/OH.2012.29351. Review. Hungarian.

PMID:
22547464
8.

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.

Chen LH, Leung PS.

Diabetes Obes Metab. 2013 May;15(5):392-402. doi: 10.1111/dom.12064. Epub 2013 Feb 6. Review.

PMID:
23331516
9.

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Dobbins RL, O'Connor-Semmes R, Kapur A, Kapitza C, Golor G, Mikoshiba I, Tao W, Hussey EK.

Diabetes Obes Metab. 2012 Jan;14(1):15-22. doi: 10.1111/j.1463-1326.2011.01462.x. Epub 2011 Oct 30.

PMID:
21733056
10.

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W.

Diabetes Technol Ther. 2011 Dec;13(12):1219-27. doi: 10.1089/dia.2011.0012. Epub 2011 Aug 19.

PMID:
21854192
11.

Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.

Nisly SA, Kolanczyk DM, Walton AM.

Am J Health Syst Pharm. 2013 Feb 15;70(4):311-9. doi: 10.2146/ajhp110514. Review.

PMID:
23370138
12.

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

Neumiller JJ, White JR Jr, Campbell RK.

Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Review.

PMID:
20205482
13.

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.

Nauck MA.

Drug Des Devel Ther. 2014 Sep 11;8:1335-80. doi: 10.2147/DDDT.S50773. eCollection 2014. Review.

14.

Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.

Said S, Hernandez GT.

Cardiovasc Hematol Agents Med Chem. 2013 Sep;11(3):203-6. Review.

PMID:
24025022
15.

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.

Idris I, Donnelly R.

Diabetes Obes Metab. 2009 Feb;11(2):79-88. doi: 10.1111/j.1463-1326.2008.00982.x. Review.

PMID:
19125776
16.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Kurosaki E, Ogasawara H.

Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Review.

PMID:
23563279
18.
20.

The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.

Lajara R.

Expert Opin Pharmacother. 2014 Dec;15(17):2565-85. doi: 10.1517/14656566.2014.968551. Epub 2014 Oct 15. Review.

PMID:
25316597
Items per page

Supplemental Content

Write to the Help Desk